|Articles|April 15, 2002
- BioPharm International-04-01-2002
- Volume 15
- Issue 4
Business Matters: Personalized Medicine or Blockbusterology?
Author(s)G. Steven Burrill
by G. Steven Burrill, Burrill & Company Biotechnology offers to change the face of medicine, if big pharma doesn't stand in the way
Advertisement
Articles in this issue
over 23 years ago
Analytical Advances: Paperless or Less Paper?over 23 years ago
Beyond QSITover 23 years ago
Determining Protein Concentration, Part 1: Methodologyover 23 years ago
Guest Editorial: The Protein Production Challengeover 23 years ago
Advances in Amino Acid AnalysisNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Charles River Incubator Cohort to Accelerate CGT Development
2
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
3
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
4
BioPharma By The Numbers: Batch Failures in Biopharma Manufacturing
5
